Perspective Therapeutics Valuation
| CATX Stock | 2.17 0.08 3.83% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Perspective Therapeutics holds a recent Real Value of USD2.08 per share. The prevailing price of the company is USD2.17. Our model determines the value of Perspective Therapeutics from analyzing the company fundamentals such as Current Valuation of (15.46 M), shares owned by insiders of 18.81 %, and Return On Equity of -0.37 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Perspective Therapeutics' valuation include:
Price Book 0.6414 | Enterprise Value | Enterprise Value Ebitda (21.91) | Price Sales 144.5269 | Enterprise Value Revenue 68.7327 |
Overvalued
Today
Please note that Perspective Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of Perspective Therapeutics is based on 3 months time horizon. Increasing Perspective Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Perspective Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Perspective Stock. However, Perspective Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.17 | Real 2.08 | Target 12.61 | Hype 2.17 | Naive 2.87 |
The intrinsic value of Perspective Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Perspective Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Perspective Therapeutics helps investors to forecast how Perspective stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Perspective Therapeutics more accurately as focusing exclusively on Perspective Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Perspective Therapeutics' intrinsic value based on its ongoing forecasts of Perspective Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Perspective Therapeutics' closest peers.
Perspective Therapeutics Cash |
|
Perspective Therapeutics Total Value Analysis
Perspective Therapeutics is currently anticipated to have valuation of (15.46 M) with market capitalization of 155.37 M, debt of 4.06 M, and cash on hands of . The negative valuation of Perspective Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Perspective Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(15.46 M) | 155.37 M | 4.06 M |
Perspective Therapeutics Asset Utilization
One of the ways to look at asset utilization of Perspective is to check how much profit was generated for every dollar of assets it reports. Perspective Therapeutics holds a negative application of assets of -0.17 pct., losing USD0.001724 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Perspective Therapeutics shows how discouraging it operates for each dollar spent on its assets.Perspective Therapeutics Ownership Allocation
Perspective Therapeutics owns a total of 74.34 Million outstanding shares. Over half of Perspective Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Perspective Therapeutics Profitability Analysis
Net Loss for the year was (79.28 M) with loss before overhead, payroll, taxes, and interest of (60.89 M).About Perspective Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Perspective Therapeutics. We calculate exposure to Perspective Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Perspective Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.6 M | 1.2 M | |
| Pretax Profit Margin | (32.16) | (30.55) | |
| Operating Profit Margin | (32.83) | (31.19) | |
| Net Loss | (37.30) | (35.43) | |
| Gross Profit Margin | 0.21 | 0.22 |
Perspective Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 64.4 M |
Perspective Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Perspective Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Perspective we look at many different elements of the entity such as Perspective's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Perspective Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Perspective Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Perspective Therapeutics' worth.Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.